LY3962673 for KRAS G12D-mutated solid tumors

Purpose of this Study

We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with a solid tumor form of cancer
  • Have disease that is inoperable, advanced, or metastatic
  • The tumor tests positive for a KRAS G12D mutation
For more information, contact the study team at dana.a.warren@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will:
  • Take the study drug by mouth once or twice every day
  • Depending on which arm of the study you are in, you may also get standard anti-cancer drugs every 1 to 2 weeks
  • Have your tumor biopsied
  • Give blood and urine samples
  • Have regular CT or MRI scans

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

[J5J-OX-JZZA] A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors

Principal Investigator

John
Strickler

Protocol Number

PRO00116471

NCT ID

NCT06586515

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov